Solasia & Meiji Enter License Agreement For Darinaparsin In Japan - Quick Facts

(RTTNews) - Solasia Pharma K.K. announced the company and Meiji Seika Pharma Co. Ltd. have entered into a license agreement for the development and commercialization of darinaparsin in Japan. Darinaparsin is a mitochondrial-targeted agent being developed for the treatment of various hematologic and solid cancers.

Solasia obtained an exclusive worldwide license to develop and commercialize darinaparsin from ZIOPHARM Oncology, Inc. (ZIOP), and the company is currently conducting clinical trials in Japan and other parts of Asia. In consideration of the license granted to Meiji, Solasia will receive an initial development payment and, upon successful development, regulatory and sales milestone payments, as well as tiered royalties. Meiji will also participate in Solasia's upcoming private placement.